argenx said Monday it will acquire Forte Biosciences in an all-cash deal worth up to $2.2 billion — $77 a share, roughly a 41% premium to Friday’s close, expected to complete in the third quarter. Forte finished the session up 39.55%. argenx finished down 1.70%.
Forte sells nothing. Its entire value is FB102, a first-in-class antibody aimed at CD122, a protein that helps regulate several classes of immune cells. The drug has positive early-stage data in celiac disease and in vitiligo, the skin condition where pigment is lost in patches. Phase 2 data are due later this year. A Phase 1b readout in alopecia areata is also expected in 2026.
So the Dutch buyer is paying $2.2 billion in cash, up front, for a molecule whose defining trial hasn’t reported. To understand why, look at what argenx already owns.
The $56 billion single point of failure
argenx is worth more than $56 billion, and essentially all of it rests on one molecule. Vyvgart was approved for myasthenia gravis in 2021, picked up a second autoimmune indication in 2024, generated more than $4 billion in 2025, and did close to $2.9 billion in the first six months of 2026 alone. That is a spectacular franchise. It is also the whole company.
Single-asset concentration is the risk that never shows up in a good quarter and shows up in every bad one — a competitor readout, a label restriction, a patent cliff, one safety signal. CEO Karen Massey framed the purchase as advancing argenx’s “ambition to be the leading immunology innovator of the future.” Translated: one drug is not a pipeline, and you do not build a second one on internal timelines alone.
Our take: The price isn’t the story. The timing is. RBC’s Luca Issi called the deal “not surprising” — argenx had already bought into Forte’s April stock offering — but flagged surprise that argenx didn’t wait for more data before “pulling the trigger on a relatively large transaction.” A buyer with a Phase 2 readout months away, and a balance sheet fed by a drug that booked close to $2.9 billion in six months, paid the pre-data price anyway. That’s not confidence in FB102. That’s a read on who else was circling.
CD122 is getting crowded
argenx isn’t alone in liking this target. Teva — in a development deal with Royalty Pharma — and First Tracks Biotherapeutics both have anti-CD122 programs in the clinic. Once a mechanism attracts three credible developers, the asset stops being cheap and starts being contested. Waiting for clean Phase 2 data would have made FB102 a better-understood drug and a far more expensive one, bought at auction.
Leerink’s Thomas Smith described FB102 as a possible “pipeline-in-a-product” — one antibody, many indications — which is precisely the shape argenx knows how to commercialize. It ran that exact play with Vyvgart: approve in one autoimmune disease, expand into the next.
What to watch
- The Phase 2 vitiligo readout, later this year. This is now argenx’s risk, not Forte shareholders’. A miss makes $2.2 billion look like an expensive lottery ticket.
- The alopecia areata Phase 1b, due in 2026. The second data point that decides whether “pipeline-in-a-product” is real or a pitch.
- Whether a rival CD122 developer moves next. Pre-emptive buying is contagious; if Teva or a larger acquirer responds, the read on argenx’s timing gets a lot kinder.
- argenx’s next deal. One acquisition doesn’t fix concentration risk. A company this dependent on a single molecule needs more than one answer.
The deal needs the usual regulatory clearances and is targeted to close in Q3. For argenx, the meter starts now: it has bought a second story to tell, and roughly four months until the market finds out whether it’s a good one.